New baby formula aims to soothe milk allergy symptoms
NCT ID NCT07484035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new extensively hydrolyzed formula for infants aged 0-5 months with mild-to-moderate cow's milk protein allergy (CMPA). The formula is designed to relieve symptoms like skin rashes, stomach issues, and breathing problems. Over 28 days, researchers will compare the new formula to an existing one to see if it works just as well and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 124 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
0 to 5 months
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for participation: * Born at 37-42 weeks gestation with birth weight 2500-4000 g * Aged 0 to 5 months at enrollment * Diagnosed with mild-to-moderate CMPA by a physician based on the Nowak-Wegrzyn (2019) diagnostic criteria, meeting any of the following prior to enrollment: (a) Typical allergic symptoms + sensitization markers * Symptoms: Clear allergic reactions (e.g., urticaria, vomiting, dyspnea) following exposure to cow's milk or dairy products * Evidence of sensitization (any one of the following): * Serum cow's milk-specific IgE \>0.7 kIU/L * Serum cow's milk-specific IgE \>0.35 kUA/L * Positive skin prick test (wheal diameter ≥5 mm) (b) High-threshold serum specific IgE * Infants aged \<1 year: Cow's milk-specific IgE ≥5 kIU/L (c) Strongly positive SPT * SPT wheal diameter ≥10 mm (regardless of age) (d) Positive oral food challenge under medical supervision * Dietary elimination for at least 2 weeks, followed by OFC provoking immediate allergic reactions (e) Physician-confirmed diagnosis * Physician-confirmed diagnosis of CMPA supported by medical records dated within 2 weeks * Written informed consent voluntarily signed by at least one parent or legal guardian * Parents or legal guardians able to understand the informed consent form and other study documents, and willing and able to comply with study requirements * Parents or legal guardians agree not to enroll the infant in any other clinical studies during the trial period Exclusion Criteria: Subjects meeting any of the following criteria are not eligible for participation: * Recent onset of allergic symptoms due to causes other than cow's milk protein (including other food allergens, inhalant allergies, contact allergies, drug allergies, insect bite allergies, etc.) * Use of any extensively hydrolyzed formula (eHF) or amino acid formula (AAF) for the treatment of cow's milk protein allergy within 1 month prior to enrollment * Known intolerance to ingredients in the study formula (e.g., lactose intolerance) * Severe cow's milk protein allergy requiring treatment with amino acid formula (AAF) * Presence of severe congenital diseases or malformations, major organ dysfunction, genetic or metabolic disorders, or infectious diseases of the gastrointestinal tract or other sites * Growth retardation due to causes other than cow's milk protein allergy, or other significant medical conditions that, in the opinion of the investigator, may affect growth and/or development * Need for specialized diets or feeding methods (e.g., amino acid formula, metabolic disorder formula, or tube feeding) * Complementary foods already introduced * Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study * Concurrent participation in another clinical study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cow's milk protein allergy (CMPA) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Beijing Jingdu Children's Hospital
Beijing, Beijing Municipality, 102208, China
-
Foshan Maternal and Child Health Hospital
Foshan, Guangdong, 528000, China
-
Sichuan Jinxin Xinan Women's and Children's Hospital
Chengdu, Sichuan, 610000, China
-
Wuxi Maternal and Child Health Hospital
Wuxi, Jiangsu, 214000, China
-
Xiangtan County Maternal and Child Health Hospital
Xiangtan, Hunan, 411200, China
-
Zhuhai Maternal and Child Health Hospital
Zhuhai, Guangdong, 519000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.